Q Biomed Inc.
501 Madison Ave, 14th Floor
42 articles with Q Biomed Inc.
9/24/2018Here's a look at who's making moves in the biotech and pharma world this week.
Distinguished Ophthalmology Specialist Brings Wealth of Experience
Q BioMed Inc. Announces FDA Filing for Strontium Chloride Sr89 Injection USP for Relief of Metastatic Cancer Bone Pain
Prior Approval Supplement Filing Under GDUFA Guidelines is Final Step in Approval Process
Q Biomed Inc. Extends its Exclusive Option Agreement With Washington University in St. Louis for a Novel Companion Biomarker for Monitoring Glaucoma and Initiates a Clinical Study
Q BioMed Inc. is pleased to announce that it is extending its option agreement with Washington University in St. Louis.
With increased worries over the addictive nature of opioid-based pain treatments, more and more companies are focusing on the development of effective treatments without the addictive nature.
Together with Mannin Research, the company has made significant progress on their Tie2 activating molecule
Company makes effort to connect with patients and caregivers as it progress its potential treatment for an Autistic Spectrum Nonverbal Developmental Disorder
Q Biomed Inc. Announces FDA Filing for Approval of a New Manufacturing Facility for Non-Opioid Strontium Chloride SR89 Injection USP for Relief of Cancer Bone Pain
Q Biomed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, and Bio-Nucleonics, licensor of Strontium 89 Chloride, announce submission of a regulatory filing to the FDA for the approval of a new manufacturing facility.
Q Biomed is pleased to welcome Dr. Rick Panicucci as an independent member on its board of Directors.
Q Biomed Signs Exclusive Option Agreement With Washington University in St. Louis for a Novel Companion Biomarker for Monitoring Glaucoma
Q Biomed is pleased to announce an exclusive option agreement with Washington University in St. Louis.
Q Biomed is pleased to announce pricing of a public offering of an aggregate of 1,711,875 shares of common stock of the Company.
Q Biomed is pleased to provide this year end update to its shareholders.
Q Biomed announced today that all convertible notes and loans have been settled in full, including the $4M of convertible notes that had been issued pursuant to a Securities Purchase Agreement dated November 29, 2016.
Q Biomed announced today that Dr. Helen Tager-Flusberg from Boston University has joined its advisory committee for QBM-001, which is being tested for pediatric developmental nonverbal disorder in toddlers within the autism spectrum disorders.
Q Biomed congratulates our collaborative research partner and licensor, Mannin Research, on receiving R&D funding from the NRC IRAP to initiate work on a Tie2-activating biologic for the treatment of glaucoma.
Q BioMed Announces Identification and Production of New Proprietary Drug Candidate for Pediatric Nonverbal Disorder
Q BioMed today that it has successfully developed a new and proprietary analog of QBM-001 in partnership with Sphaera Pharma for its intended use in pediatric developmental nonverbal disorder.